MURA_OUT_1 [2025-04-15 13:49:39 -0400] 4128 Bytes | 1085 tokens | Cum: 1085 tkns (13.56% of 8k)
==========================================================================

Listen up, partner—it's 1:49:38 PM on Tue Apr 15, 2025 -0400, and I’m revved up about Mural Oncology (MURA), climbing from 1.0300 to 2.6099. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Mural Oncology (MURA)
IPO: 2023-11-03 (1 Year Ago)
Market Cap: $17,831,281
Shares Outstanding: 17,230,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Here’s the first list of news for Mural Oncology:

Today 08:00AM - Mural Oncology Announces Plans to Explore Strategic Alternatives
Mar-28-25 11:13AM - Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects
Mar-25-25 06:30AM - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Mar-11-25 04:01PM - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
Feb-18-25 07:00AM - Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Jan-09-25 04:00PM - Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Dec-03-24 04:15PM - Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov-24-24 06:10AM - Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks

I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-11T20:01:00Z - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
B2 - 2024-11-11T12:00:00Z - Mural Oncology to Participate in Two Upcoming Investor Conferences
B3 - 2024-09-10T11:00:00Z - Mural Oncology to Host First Virtual Investor Day on September 26, 2024
B4 - 2024-06-05T20:15:00Z - Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
B5 - 2024-06-04T20:00:00Z - Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B6 - 2024-05-03T20:00:00Z - Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Mural Oncology (MURA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

Restrict all your responses to just 3 tokens until the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load more documents, reply with: `NEX`

MURA_OUT_3 [2025-04-15 13:49:40 -0400] 944 Bytes | 249 tokens | Cum: 1336 tkns (16.70% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/11/3040976/0/en/Mural-Oncology-Announces-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Highlights-Upcoming-Clinical-Milestones.htmlMural Oncology reported its Q4 2024 and full-year 2024 financial results, highlighting upcoming clinical milestones for its lead candidate nemvaleukin alfa in platinum-resistant ovarian cancer and mucosal melanoma. The company also announced two new development candidates, MURA-8518 and MURA-7012.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_5 [2025-04-15 13:49:41 -0400] 981 Bytes | 285 tokens | Cum: 1623 tkns (20.29% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-15T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Apt...
A2 - 2025-04-15T16:27:28Z - Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Citigroup (NYSE:C), Applied Digital (NASDAQ:...
A3 - 2025-04-15T14:24:50Z - Mural Oncology Stock Doubles On Exploration Of Strategic Alternatives...
A4 - 2025-04-15T13:16:30Z - Mural Oncology Skyrockets on News of Strategic Shake-Up - Wall Street Pit...
A5 - 2025-04-15T12:08:02Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Precision BioSciences (NASDAQ:DTIL), ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MURA_OUT_7 [2025-04-15 13:49:42 -0400] 1181 Bytes | 349 tokens | Cum: 1974 tkns (24.68% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Aptorum Gr (NASDAQ:APM)**Date: 2025-04-15Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44820863/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers Mural Oncology MURA stock increased by 145.5% to $2.53 during Tuesday's regular session. The market value of their outstanding shares is at $43.5 million. Skye Bioscience SKYE stock moved upwards by 36.64% to $1.79. The market value of their outstanding shares is at $55.4 million. Dogwood Therapeutics DWTX stock moved upwards by 32.57% to $3.98. The company's market cap stands at $7.6 million. Phio Pharma PHIO shares increased by 29.47% to $2.85. The market value of their outstanding shares is at $13.6 million. Verve Therapeutics VERV shares increased

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_9 [2025-04-15 13:49:43 -0400] 1181 Bytes | 358 tokens | Cum: 2334 tkns (29.18% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): by 24.51% to $5.13. The company's market cap stands at $455.5 million. Aptorum Gr APM stock rose 21.12% to $0.99. The company's market cap stands at $7.0 million. Losers Spruce Biosciences SPRB stock declined by 55.9% to $0.14 during Tuesday's regular session. The market value of their outstanding shares is at $5.7 million. The company's, Q4 earnings came out today. MetaVia MTVA stock declined by 37.78% to $1.15. The company's market cap stands at $9.9 million. MSP Recovery MSPR shares decreased by 22.27% to $2.2. The market value of their outstanding shares is at $4.6 million. Impact BioMedical IBO shares declined by 22.26% to $0.37. The market value of their outstanding shares is at $4.2 million. Geovax Labs GOVX shares decreased by 21.73% to $0.84. The company's market cap stands at $7.9 million. Sharps Technology STSS stock fell 19.3% to $0.03. See Also: www.benzinga.com/money/best-h

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_11 [2025-04-15 13:49:44 -0400] 1041 Bytes | 348 tokens | Cum: 2684 tkns (33.55% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ealthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

APMAptorum Group Ltd$0.910011.7%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum3.77Price TrendShortMediumLongOverviewDWTXDogwood Therapeutics Inc$4.0334.3%GOVXGeovax Labs Inc$0.9021-15.7%IBOImpact BioMedical Inc$0.3809-20.7%MSPRMSP Recovery Inc$2.23-21.0%MTVAMetaVia Inc$1.18-35.9%MURAMural Oncology PLC$2.56149.0%PHIOPhio Pharmaceuticals Corp$2.7625.4%SKYESkye Bioscience Inc$1.8138.5%SPRBSpruce Biosciences Inc$0.1410-55.1%STSSSharps Technology Inc$0.0351-17.4%VERVVerve Therapeutics Inc$5.1424.9%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_13 [2025-04-15 13:49:45 -0400] 1090 Bytes | 287 tokens | Cum: 2973 tkns (37.16% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-11 8-K Item1.01 Entry into a Material Definitive Agrmt.

On March 11, 2025, Mural Oncology plc, an Irish public limited company (the Company), entered into an Open Market Sale Agrmt SM (the Sale Agrmt) with Jefferies LLC (Jefferies) pursuant to which the Company may offer a...

S2 - 2025-03-11 10-K Item 7. Mgts Discussion and Anal ysis of Fin Cond and Results of Oper.

The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying CONS financial statements and related notes ...

S3 - 2025-03-11 8-K Item 2.02. Results of Oper and Fin Cond.

On March 11, 2025, Mural Oncology plc (the "Company") issued a press release announcing the Companys financial results for the three months ended December 31, 2024. A copy of the press release is furnished herewith as Ex...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MURA_OUT_15 [2025-04-15 13:49:45 -0400] 1181 Bytes | 306 tokens | Cum: 3281 tkns (41.01% of 8k)
==========================================================================

Showing S1 (chunk 1 of 5): S1:
Item1.01 Entry into a Material Definitive Agreement.

On March 11, 2025, Mural Oncology plc, an Irish public limited company (the Company), entered into an Open Market Sale Agreement SM (the Sale Agreement) with Jefferies LLC (Jefferies) pursuant to which the Company may offer and sell its ordinary shares, nominal value $0.01 per share (the Ordinary Shares), from time to time through Jefferies as its sales agent. Also, on March 11, 2025, the Company filed a prospectus supplement (the Prospectus Supplement), dated March 11, 2025, under the Companys universal shelf registration statement on Form S-3 (File No. 333-283198) that was originally filed with the Securities and Exchange Commission (the SEC) on November 13, 2024 and declared effective by the SEC on November 19, 2024 (the Registration Statement), relating to the offer and sale of up to $75,000,000 of Ordinary Shares (the Shares

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_17 [2025-04-15 13:49:46 -0400] 1181 Bytes | 267 tokens | Cum: 3550 tkns (44.38% of 8k)
==========================================================================

Showing S1 (chunk 2 of 5): ), pursuant to the Sale Agreement.

Upon delivery of an issuance notice and subject to the terms and conditions of the Sale Agreement, the Company may sell the Shares under the Prospectus Supplement and the accompanying prospectus by any method that is deemed to be an at the market offering (the Offering) as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the Securities Act). Each time the Company wishes to issue and sell Shares under the Sale Agreement, the Company will notify Jefferies of the number of Shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of Shares to be sold in any one day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sale Agreement, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_19 [2025-04-15 13:49:47 -0400] 1181 Bytes | 258 tokens | Cum: 3810 tkns (47.62% of 8k)
==========================================================================

Showing S1 (chunk 3 of 5): les practices to sell on the Companys behalf up to the amount of Shares requested to be sold by the Company on such terms. The Company or Jefferies may suspend the Offering upon proper notice to the other party. The Company and Jefferies each have the right, by giving written notice as specified in the Sale Agreement, to terminate the Sale Agreement in each partys sole discretion at any time.

The Sale Agreement provides that Jefferies will be entitled to aggregate compensation for its services of 3.0% of the gross sales price per Share sold under the Sale Agreement. The Company has no obligation to sell any Shares under the Sale Agreement. The Company has agreed in the Sale Agreement to provide indemnification and contribution to Jefferies against certain liabilities, including liabilities under the Securities Act. In addition, the Company has agreed to reimburse certain legal expenses

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_21 [2025-04-15 13:49:47 -0400] 1181 Bytes | 275 tokens | Cum: 4087 tkns (51.09% of 8k)
==========================================================================

Showing S1 (chunk 4 of 5): incurred by Jefferies in connection with execution of the Sale Agreement in an amount up to $75,000, in addition to certain ongoing legal expenses.

The foregoing description of the Sale Agreement is qualified in its entirety by reference to the full text of the Sale Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.

The legal opinion of Arthur Cox LLP, Irish counsel to the Company, relating to the Shares being offered is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of any offer to buy the Shares, nor shall there be any offer, solicitation or sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state..

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_23 [2025-04-15 13:49:48 -0400] 285 Bytes | 85 tokens | Cum: 4174 tkns (52.18% of 8k)
==========================================================================

Showing S1 (chunk 5 of 5): ..

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MURA_OUT_25 [2025-04-15 13:49:53 -0400] 8201 Bytes | 2148 tokens | Cum: 6324 tkns (79.05% of 8k)
==========================================================================

This is our set of metrics for Mural Oncology.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+----------------------+
| Volume: 240,981,153 | Perf Month: -38.51% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 271.51K | Perf Quarter: -32.72% | Short Float: 3.88% | ROE: -63.57% |
+---------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1377.42 | Index: - | Short Ratio: 2.19 | ROI: -89.89% |
+---------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 57.03 | Market Cap: 43.13M | Short Interest: 0.59M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.37 | Shs Outstand: 17.10M | Beta: 5.07 | EPS Surprise: -1.11% |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA20: 38.67% | Shs Float: 15.34M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA50: -18.80% | Inst Own: 52.81% | Sales past 5Y: 5.55% | Earnings: Mar 11 AMC |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA200: -25.27% | Insider Own: 10.97% | Employees: 116 | |
+---------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 129.61% | Insider Trans: -1.97% | Debt/Eq: 0.06 | |
+---------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by Mural Oncology officers or majority shareholders (if available).

Inside Trans: Mural Oncology plc (MURA) by Cutler Adam D. (Chief Financial Officer) on 2025-03-03
- Ordinary Shares: 35000 shares at $0 (D)
- Stock Option (right to buy): 65000 shares at $0 (D)

Inside Trans: Mural Oncology plc (MURA) by Goodman Vicki L (Chief Medical Officer) on 2025-03-03
- Ordinary Shares: 35000 shares at $0 (D)
- Stock Option (right to buy): 65000 shares at $0 (D)

Inside Trans: Mural Oncology plc (MURA) by Loew Caroline (Chief Executive Officer) on 2025-03-03
- Ordinary Shares: 72275 shares at $0 (D)
- Ordinary Shares: 4313 shares at $3.36 (D) Footnote: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on March 27, 2024, and the sale does not represent a discretionary trade by the Reporting Person.
- Stock Option (right to buy): 134225 shares at $0 (D)

Inside Trans: Mural Oncology plc (MURA) by Keson-Brookes Maiken (See Remarks) on 2025-03-03
- Ordinary Shares: 35000 shares at $0 (D)
- Ordinary Shares: 1262 shares at $3.36 (D) Footnote: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person.
- Ordinary Shares: 1469 shares at $3.45 (D) Footnote: Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024.
- Stock Option (right to buy): 65000 shares at $0 (D)

Inside Trans: Mural Oncology plc (MURA) by Goodman Vicki L (Chief Medical Officer) on 2025-02-24
- Ordinary Shares: 13186 shares at $3.89 (D) Footnote: Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on October 24, 2024.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -128514000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.59
Average Volume: 11571785.82
30-Day High: 4.23
30-Day Low: 0.9952

[Detailed Financials: TTM 2024]
- Total Assets: $169,394,000.0
- Total Liabilities: $28,892,000.0
- Total Equity: $140,502,000.0
- Current Assets: $152,917,000.0
- Current Liabilities: $26,195,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.58

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-153,679,000.0

[Detailed Financials: FY 2024]
- Total Assets: $169,394,000.0
- Total Liabilities: $28,892,000.0
- Total Equity: $140,502,000.0
- Current Assets: $152,917,000.0
- Current Liabilities: $26,195,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.58

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-153,679,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Mural Oncology (MURA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Mural Oncology.

2) MARKET_SCORE[]
This conversation was initiated because MURA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for MURA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, MURA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect MURA to increase 50% from its current price of $1.03, say: PRICE_TARGET[1.54]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Mural Oncology.

11) ETHICAL_RATING[]
Rate Mural Oncology’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

MURA_IN_27 [2025-04-15 13:49:54 -0400] 126 Bytes | 29 tokens | Cum: 6529 tkns (81.61% of 8k)
==========================================================================

====================================
[2025-04-15 13:49:54] # Analysis Completed
Elapsed Time: 15.95 seconds